thiopalmitamide | 45221-35-0

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫代酰胺
• 英文名称: thiopalmitamide
• 英文别名: Thiopalmitamid；Thiohexadecansaeure-amid；Hexadecanethioamide
• CAS: 45221-35-0
• 化学式: C₁₆H₃₃NS
• 分子量: 271.511
• InChiKey: HRLSQPDJQBQISE-UHFFFAOYSA-N

物化性质

• 沸点：
  372.9±25.0 °C(Predicted)
• 密度：
  0.901±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  7.1
• 重原子数：
  18
• 可旋转键数：
  14
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  58.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  thiopalmitamide 生成 十六腈
  参考文献：
  名称：

  Ralston; van der Wal; McCorkle, Journal of Organic Chemistry, 1939, vol. 1, p. 69

  摘要：

  DOI：
• 作为产物：
  描述：

  十六腈 在 乙醇 、 硫化氢 、 氨 作用下， 生成 thiopalmitamide
  参考文献：
  名称：

  Ralston; van der Wal; McCorkle, Journal of Organic Chemistry, 1939, vol. 4, p. 69

  摘要：

  DOI：

文献信息

• STABILIZATION OF HYDROXYLAMINE CONTAINING SOLUTIONS AND METHOD FOR THEIR PREPARATION
  申请人：Lee Wai Mun

  公开号：US20090112024A1

  公开（公告）日：2009-04-30

  The invention relates to the use of amidoximes for prevention of or stabilization of hydroxylamine compounds against undesired decomposition.

  本发明涉及将酰胺肟用于预防或稳定羟基胺化合物，防止其不受控分解。
• Synthesis and characterization of two new benzothiadiazole- and fused bithiophene based low band-gap D–A copolymers: Application as donor bulk heterojunction polymer solar cells
  作者：M.L. Keshtov、G.D. Sharma、S.A. Kuklin、I.Е. Ostapov、D.Yu. Godovsky、A.R. Khokhlov、F.C. Chen

  DOI：10.1016/j.polymer.2015.03.058

  日期：2015.5

  P2, respectively) which show that copolymers has good stability in the air and assured a higher open circuit voltage when it photovoltaic application. These copolymer were used as donor along with PC71BM and the BHJ polymer solar cells based on P1:PC71BM and P2:PC71BM processed with chloroform (CF) solvent showed over all PCE of 4.54% and 4.36%, respectively. Additionally, the PCE was improved up to

  通过Stille交叉偶联聚合反应，合成了两种新的窄带隙D–A共轭共聚物P1和P2，它们含有不同的稠合噻吩供体单元和相同的苯并噻二唑受体单元，并通过1 H NMR，元素分析和GPC，TGA，DSC进行了表征。循环伏安法测量表明，两种共聚物的HOMO能级都很深（P1和P2分别为-5.10和-5.35 eV ），这表明该共聚物在空气中具有良好的稳定性，并在光伏应用中确保了较高的开路电压。这些共聚物与PC 71 BM和基于P1：PC 71的BHJ聚合物太阳能电池一起用作施主BM和P2：PC 71用氯仿（CF）溶剂处理的BM的所有PCE分别显示为4.54％和4.36％。此外，用DIO（4 v％）/ CF溶剂处理的P1：PC 71 BM和P2：PC 71 BM活性层的PCE分别提高了5.62％和5.24％。PCE的增强归因于活性层的纳米级形态和晶体性质的改善，以及由于添加了DIO而在器件中进行的电荷传
• MULTI-TARGET MODULATION FOR TREATING FIBROSIS AND INFLAMMATORY CONDITIONS
  申请人：Aadigen, LLC

  公开号：EP3424511A1

  公开（公告）日：2019-01-09

  The present invention relates to compositions comprising one or more active agents that selectively modulate the expression of two or more genes, for example at the post-transcription level, that are involved in fibrosis and/or inflammatory conditions. Also provided are methods of using such compositions for treating fibrotic diseases, as well as other diseases including inflammatory diseases and cancer.

  本发明涉及包含一种或多种活性剂的组合物，这些活性剂可选择性地调节参与纤维化和/或炎症的两种或多种基因的表达，例如在转录后水平。本发明还提供了使用此类组合物治疗纤维化疾病以及包括炎症性疾病和癌症在内的其他疾病的方法。
• Methods of liver disease treatment
  申请人：Hudnall Michael

  公开号：US11252984B2

  公开（公告）日：2022-02-22

  Methods for treatment of chronic liver disease and reversing liver fibrosis are provided. These treatments may be achieved using a medical food composition. The medical food is configured specifically for those having chronic liver disease to provide for specific nutritional requirements caused by the chronic liver disease. Testing of the treated patient allows for tracking of progress and to determine if the liver fibrosis is reversed.

  提供了治疗慢性肝病和逆转肝纤维化的方法。这些治疗可通过一种医用食品组合物来实现。医用食品专为慢性肝病患者配置，以满足慢性肝病引起的特定营养需求。对接受治疗的患者进行检测，可以跟踪进展情况，并确定肝纤维化是否得到逆转。
• Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer
  申请人：——

  公开号：US20020156033A1

  公开（公告）日：2002-10-24

  The invention involves administration of an immunostimulatory nucleic acid in combination with a cancer medicament for the treatment or prevention of cancer in subjects. The combination of drugs are administered in synergistic amounts or in various dosages or at various time schedules. The invention also relates to kits and compositions concerning the combination of drugs.

  本发明涉及将免疫刺激核酸与抗癌药物联合使用，用于治疗或预防受试者的癌症。药物组合以协同量或不同剂量或不同时间安排给药。本发明还涉及有关药物组合的试剂盒和组合物。